Conversely, despite the negative cytological results obtained for the two CCA patients included in this investigation, one CCA patient had the highest number of mutations in several genes, i.e., KRAS, TP53, CDKN2A, RNF43, and BRAF, all of which are relevant and have reported evidence for the impact of targeted therapies on CCAs [64,65]. The gene discussed is KRAS; the disease is cholangiocarcinoma.